Drug Trial Radar · NCT07717918
A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Jul 6, 2026
Primary completion
Aug 5, 2026
Study completion Aug 5, 2026
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Jul 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Single center, double-masked study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Subjects
Conditions
- Healthy
Interventions
BL1332 eye dropsDrug
Taken 1 time
BL1332 Placebo eye dropsDrug
Taken 1 time
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular pain severity assessed by numeric pain rating scale (NPRS)Time frame: Assessed 5 seconds post-capsaicin dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site 101
Newport Beach, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.